

Kerri Kaplan, President and CEO Lustgarten Foundation



World Pancreatic Cancer Coalition
The Science of Pancreatic Cancer: A Global Perspective
May 8, 2019





- The cumulative research spend has increased from \$200,000,000 in 2016 to \$260,000,000 in 2018 by organizations in the World Pancreatic Cancer Coalition
- This investment spans research in biology, early detection, and treatment
- 41 WPCC member organizations fund research

This funding is making a


CancerSEEK Blood Test

- Developed for 8 cancers including pancreatic:
 - Tested in patients with early stages of cancer
 - <u>Specificity is 99%</u> and sensitivity is 70% for pancreatic cancer
 - Fast track status from FDA for pancreatic and ovarian cancers, growing interest from industry

Next Steps:

- Continue to improve the sensitivity and the overall test
- Follow 50,000 healthy individuals

Better Imagining: FELIX project



- Teach computers to detect smaller pancreatic tumors on CT scans
- Designed by the "driverless car" team
- Approx. 25% of pancreatic cancers detected on the scans by FELIX imaging were not detected by the radiologist
- Goal is to commercialize a rapid, reliable test that can be used in the clinic

WORLD PANCREATIC CANCER COALITION

Personalized Medicine – Genetic Testing

- Genetic testing recommended for all pancreatic cancer patients as the new standard of care
- At some academic centers like Dana Farber, patients get genetic sequencing of both the tumor and inherited DNA
- At DF, they published that approximately 1/3 of patients had a mutation or genetic alteration that was treated with a therapy either in clinical trials or used for other types of cancer

Better Therapy: Personalized Medicine - Organoids



- Lustgarten, SU2C and Pancreatic Cancer Canada funding the clinical trial to determine which standard of care a patient would benefit from the most
- Next step is to use organoids to test investigational therapies for those that won't respond to standard of care

Clinical Trials Example Lustgarten-SU2C New Therapies Challenge


- Seven teams with potential to go in to clinical trials in a year
- One team at Huntsman Cancer Institute now has a new combination drug treatment with promising clinical results. Published in Nature Medicine, 3/19
- Pancan funded the preclinical work at UNC



WORLD PANCREATIC
CANCER COALITION

Drugs for 2 Days Drugs f

Drugs for 2 Months



GENetic Education, Risk Assessment, and Testing Study (generatestudy.org)



- Test family members who have a close relative with pancreatic cancer caused by an inherited mutation
- Includes genetic counseling
- First in-human prevention trials using a vaccine
- New biomarkers that can strengthen the work of CancerSEEK

GENERATE 2.0

- Test all patients for germline mutations, provide genetic counseling
- Include high-risk family members of patients without a known mutation
- Nationwide screening program, MRI/MRCP done locally, read by centralized study radiologists
- Create the most comprehensive publicly available blood sample and imaging biobank for research



Barbara Kenner, PhD

Founder, Kenner Family Research Fund



Talia Golan, MD

Medical Director, Phase I Program and Sheba Pancreatic Program, Chaim Sheba Medical Centre (Israel)



Diane Simeone, MD

Professor of Surgery and Pathology
Director, Pancreatic Cancer Center
Associate Director, Translational Research
Perlmutter Cancer Center/NYU Langone Health
(NYC, New York)



The Science of Pancreatic Cancer: A Global Perspective



Early Detection



Treatment Options



Clinical Trials



Genetic Mutations &

Familial Pancreatic Cancer



Most Exciting Developments



Questions



Importance of Advocacy



Thank You



WORLD PANCREATIC CANCER COALITION

CORAL GABLES, FLORIDA | 2019